Paul J. Scheel Jr., MD; Nancy Feeley, CRNP; Stephen M. Sozio, MD, MHS
Small case series suggest that a combination of mycophenolate mofetil and prednisone may be an effective treatment for patients with retroperitoneal fibrosis.
To describe the outcomes of adults with retroperitoneal fibrosis who received a combination of prednisone and mycophenolate mofetil.
Prospective case series of patients followed between 1 April 2005 and 1 July 2009.
Single tertiary care facility.
28 patients with retroperitoneal fibrosis.
Prednisone, 40 mg/d, tapered over 6 months, and mycophenolate mofetil, 1000 mg twice daily, for a mean of 24.3 months.
Clinical course, laboratory assessment, and measurement of periaortic mass. Mean follow-up was 1012 days, and no patients were lost to follow-up.
Systemic symptoms resolved in all patients; 89% had a 25% or greater reduction in periaortic mass. Elevated erythrocyte sedimentation rate and serum creatinine level and decreased hemoglobin level normalized in all patients. Disease recurred in 2 of 28 patients.
This was a small case series.
Combined prednisone and mycophenolate mofetil therapy is a potentially effective treatment for retroperitoneal fibrosis that warrants evaluation in randomized trials.
Scheel PJ, Feeley N, Sozio SM. Combined Prednisone and Mycophenolate Mofetil Treatment for Retroperitoneal Fibrosis: A Case Series. Ann Intern Med. 2011;154:31–36. doi: 10.7326/0003-4819-154-1-201101040-00005
Download citation file:
Published: Ann Intern Med. 2011;154(1):31-36.
Nephrology, Prevention/Screening, Urological Disorders.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use